Clinical experience with chlorpro-pamide.
Seventy-eight patients with mild diabetes were treated with chlorpropamide in doses up to 1 gm. daily. Eight showed primary failure to respond and two showed an initial but not a sustained response. Patients whose diabetes was of recent onset and who had not been treated with insulin or a sulfonylurea, required smaller doses than the remainder except for a group of patients who had been diabetic for more than 15 years. The average dose for the 64 patients who took chlorpropamide for more than three months was 0.46 gm. per day. Serious side effects were uncommon and disappeared when the drug was stopped. One patient became jaundiced, one had a rash, and one showed granulocytopenia. Changes in liver function tests were seen in 17 out of 56 patients treated for more than three months and were correlated with the dosage of the drug and the duration of treatment.
D002744:Chlorpheniramine; D002747:Chlorpropamide; D006801:Humans; D007004:Hypoglycemic Agents / Q000628:therapy*; D013453:Sulfonylurea Compounds
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D002744:Chlorpheniramine; D002747:Chlorpropamide
ANTIDIABETICS/therapy